Cargando…
IGFBP2 Is a Potential Master Regulator Driving the Dysregulated Gene Network Responsible for Short Survival in Glioblastoma Multiforme
Only 2% of glioblastoma multiforme (GBM) patients respond to standard therapy and survive beyond 36 months (long-term survivors, LTS), while the majority survive less than 12 months (short-term survivors, STS). To understand the mechanism leading to poor survival, we analyzed publicly available data...
Autores principales: | Kalya, Manasa, Kel, Alexander, Wlochowitz, Darius, Wingender, Edgar, Beißbarth, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239365/ https://www.ncbi.nlm.nih.gov/pubmed/34211498 http://dx.doi.org/10.3389/fgene.2021.670240 |
Ejemplares similares
-
Computational Identification of Key Regulators in Two Different Colorectal Cancer Cell Lines
por: Wlochowitz, Darius, et al.
Publicado: (2016) -
Prognostic and Predictive Value of an Immunoscore Signature in Glioblastoma Multiform
por: Tang, Xiangjun, et al.
Publicado: (2020) -
A Novel Six-mRNA Signature Predicts Survival of Patients With Glioblastoma Multiforme
por: Liu, Zhentao, et al.
Publicado: (2021) -
A Six-lncRNA Signature for Immunophenotype Prediction of Glioblastoma Multiforme
por: Gao, Ming, et al.
Publicado: (2021) -
Gene-Expression Analysis Identifies IGFBP2 Dysregulation in Dental Pulp Cells From Human Cleidocranial Dysplasia
por: Greene, Stephen L., et al.
Publicado: (2018)